Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon‐α: Histological evaluation by a modified histological activity index scoring system
- 1 January 1998
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 13 (1) , 68-74
- https://doi.org/10.1111/j.1440-1746.1998.tb00548.x
Abstract
The aim of the present study was to investigate the histological changes effected by interferon (IFN) treatment and to evaluate the clinical significance of serum hyaluronic acid (HA) as a marker of fibrosis. Forty-nine patients with chronic hepatitis C treated with IFN-α were divided into three groups according to the existence of viraemia: sustained complete responders (CR), complete responders with relapse (PR) and non-responders (NR). Needle biopsy sections of the liver taken before and at the end of IFN treatment were assessed according to the modified histological activitindex (HAI) scoring system. Serum fibrosis markers, including HA, were measured at needle biopsies. Biopsies of CR at the end of treatment showed a significant improvement in fibrosis and necroinflammatory scores. More significant correlation was observed between fibrosis scores and serum levels of HA before IFN treatment (r= 0.607, P < 0.0001) than those between fibrosis scores, on the one hand, and pepride of type III procollagen (PIIIP; r= 0.531, P= 0.0004) or type IV collagen 7S domain (type IV-C; r= 0.241, P= 0.1062) on the other. Moreover, serum HA levels fell significantly in patients in whom fibrosis improved (P= 0.011). This is the first paper describing the advantages of the modified HAI scoring system over others in estimating the effect of IFN-α; the results also indicate that serum HA can be useful in monitoring liver fibrosis in chronic hepatitis C patients treated with IFN-α.Keywords
This publication has 27 references indexed in Scilit:
- A histopathological study of the effects of 6-month versus 12-month interferon α-2b therapy in chronic hepatitis CJournal of Hepatology, 1996
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995
- Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alphaJournal of Hepatology, 1995
- Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α-interferon therapyJournal of Hepatology, 1995
- Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C: Effects on inflammation, fibrogenesis and viremiaJournal of Hepatology, 1993
- Transforming Growth Factors β1 and α in Chronic Liver DiseaseNew England Journal of Medicine, 1991
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- Transforming growth factors (TGFα and TGFβH) stimulate chondroitin sulfate and hyaluronate synthesis in cultured rat liver fat storing cellsFEBS Letters, 1989
- A Comparison of the Indocyanine Green and Electromagnetic Techniques in Normal and Abnormal Flow States in the DogAnnals of Surgery, 1977